Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dose-finding designs for HIV studies.

J O'Quigley1, M D Hughes, T Fenton

  • 1Department of Mathematics, University of California at San Diego, La Jolla 92093, USA. oquigley@math.ucsd.edu

Biometrics
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HIV testing uptake among the household contacts of multidrug-resistant tuberculosis index cases in eight countries.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2019
Same author

Resource utilization for multidrug-resistant tuberculosis household contact investigations (A5300/I2003).

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2018
Same author

Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.

Statistics in medicine·2011
Same author

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

The New England journal of medicine·2010
Same author

Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

HIV medicine·2010
Same author

Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2009
Same journal

Fast penalized generalized estimating equations for large longitudinal functional datasets.

Biometrics·2026
Same journal

Causally-interpretable random-effects meta-analysis.

Biometrics·2026
Same journal

Statistical inference for mean function of partially observed functional time series.

Biometrics·2026
Same journal

Subgroup identification via Interaction Tree and Mixed Model for Repeated Measures with application to Alzheimer's disease.

Biometrics·2026
Same journal

Finite mixtures of linear quantile regressions with concomitant variables: a solution to endogeneity in longitudinal data modeling.

Biometrics·2026
Same journal

Discussion on "INTACT: a method for integration of longitudinal physical activity data from multiple sources" by Jingru Zhang, Erjia Cui, Hongzhe Li, and Haochang Shou.

Biometrics·2026
See all related articles

New HIV early dose-finding designs incorporate efficacy and toxicity data. These adaptive trials identify optimal doses by sequentially analyzing viral reduction, aiming for maximum patient success or early closure if ineffective.

Area of Science:

  • Clinical Pharmacology
  • Infectious Diseases
  • Biostatistics

Background:

  • Traditional Phase I cancer trials primarily focus on toxicity.
  • Early HIV drug development requires evaluating both safety and efficacy simultaneously.
  • Existing dose-finding methods may not adequately capture crucial efficacy signals in early HIV studies.

Purpose of the Study:

  • To introduce novel, adaptive designs for early-phase dose-finding studies in HIV treatment.
  • To integrate efficacy (viral reduction) alongside toxicity assessments.
  • To identify optimal HIV drug doses maximizing successful patient outcomes.

Main Methods:

  • Sequential incorporation of viral reduction data during the trial.
  • Dose regimens ordered by toxic potential.

Related Experiment Videos

  • Classification of patient outcomes into toxicity, viral failure, or success.
  • Development of designs with good operating characteristics for dose identification.

    • Main Results:

    • The proposed designs efficiently identify doses with the highest success rates under specific assumptions.
    • Under more realistic assumptions, designs can identify doses meeting a target success rate.
    • Designs facilitate early trial closure if the treatment proves ineffective.

    Conclusions:

    • These simple, adaptive designs offer a practical approach for early HIV dose-finding.
    • Integrating efficacy data enhances the informativeness of early-phase trials.
    • The designs provide a framework for optimizing HIV treatment selection based on both safety and effectiveness.